Art

J-GLOBAL ID：201702268596667430   Reference number：17A0135720

Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy

可逆性心筋症を伴う,併用化学療法の治療が成功した侵襲性TAFRO症候群

Author (10)： Yasuda Shunichiro (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Tanaka Keisuke (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Ichikawa Ayako (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Watanabe Ken (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Uchida Emi (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Yamamoto Masahide (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Yamamoto Kouhei (Department of Comprehensive Pathology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Mizuchi Daisuke (Department of Hematology, Tokyo Teishin Hospital, Tokyo, Japan) ,  Miura Osamu (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan) ,  Fukuda Tetsuya (Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 104  Issue： 4  Page： 512-518  Publication year： Oct. 2016 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *lymphatic disease ,...
Semi thesaurus term： *TAFRO Syndrome

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0135720&from=J-GLOBAL&jstjournalNo=F0888A") }}

Author keywords (5)： TAFRO syndrome ,  Cardiomyopathy ,  Combination chemotherapy ,  IL-6 ,  Adriamycin

JST classification (1)： Clinical hematology in general  (GK01030Y)

Substance index (4)： Doxorubicin hydrochloride ,  Cyclophosphamid ,  Vincristine sulfate ,  Prednisolone

Reference (16)：

• Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57-61.
• Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220-6.
• Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy-a case report. Exp Hematol Oncol. 2015;4(1):3.
• Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015;90(11):1091-2.
• Jouvray M, Terriou L, Meignin V, Bouchindhomme B, Jourdain M, Lambert M, et al. Pseudo-adult Still’s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman’s disease. Discussion of TAFRO syndrome. Rev Med Interne. 2016;37(1):53-7.

Terms in the title (7)： 可逆性 ,  心筋症 ,  併用化学療法 ,  治療 ,  成功 ,  侵襲性 ,  TAFRO症候群